Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOLIFE SOLUTIONS INC Director's Dealing 2021

Feb 20, 2021

32106_dirs_2021-02-19_4c6c4630-03d9-4265-8b04-5948aa8d48cb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2021-02-08

Reporting Person: Berard Todd (Chief Marketing Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-08 Common Stock A 3610 Acquired 67488 Direct
2021-02-08 Common Stock M 12982 Acquired 80470 Direct
2021-02-17 Common Stock S 1842 $41.55 Disposed 78628 Direct
2021-02-18 Common Stock S 1882 $40.67 Disposed 76746 Direct
2021-02-19 Common Stock S 1876 $40.76 Disposed 74870 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-08 Restricted Stock Award $0 A 3610 Acquired Common Stock (3610) Direct

Footnotes

F1: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation.

F2: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F3: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F4: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.